MarketCap
Facebook
X
TelegramFluidigm Corporation Balance Sheet 2020-2011 | FLDM
Brief overview of Fluidigm Corporation's balance sheet strength
The comparison uses five available annual reports from the 2016–2020 interval.
Assets increased +6%, from $306.4 million to $324.8 million. The business expanded, but without sharp acceleration.
Liability growth of -26.6% trailed asset growth of +6%. The funding structure became more resilient.
Cash exceeds interest-bearing debt, producing net debt of -$5.4 million. The balance sheet therefore carries a net cash position.
What the balance sheet shows
Fluidigm Corporation's balance sheet is broadly resilient, though selected areas require monitoring. The balance between assets, equity and liabilities remains the key issue.
Annual Balance Sheet Fluidigm Corporation
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-5.38 M | 69.1 M | 76.7 M | 142 M | 184 M | 232 M | 243 M | -35.3 M | -58.6 M | -3.42 M |
Long Term Debt |
54.2 M | 53.8 M | 172 M | 195 M | 195 M | 196 M | 195 M | - | - | 1.22 M |
Total Non Current Liabilities |
131 M | 78.4 M | 194 M | 223 M | 224 M | 226 M | 228 M | 2.55 M | 1.48 M | 2.26 M |
Total Current Liabilities |
54.2 M | 32.8 M | 37.6 M | 33.5 M | 29.5 M | 30.1 M | 29.4 M | 18 M | 11.6 M | 20.2 M |
Total Liabilities |
186 M | 111 M | 232 M | 256 M | 253 M | 256 M | 257 M | 20.5 M | 13.1 M | 22.4 M |
Deferred Revenue |
13.5 M | 11.8 M | 11.5 M | 10.2 M | 9.16 M | 9.42 M | 6.93 M | 2.72 M | 1.89 M | 2.01 M |
Retained Earnings |
- | -624 M | -559 M | -500 M | -439 M | -363 M | -310 M | -257 M | -241 M | -222 M |
Total Assets |
325 M | 265 M | 304 M | 287 M | 306 M | 371 M | 408 M | 117 M | 114 M | 79.3 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Fluidigm Corporation, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Diagnostics research
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
IDEXX Laboratories
IDXX
|
$ 523.55 | 1.15 % | $ 42.1 B |  USA |
 |
Illumina
ILMN
|
$ 215.12 | 3.94 % | $ 33.3 B | USA |
 |
IQVIA Holdings
IQV
|
$ 262.27 | 2.95 % | $ 45.1 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 100.77 | 0.01 % | $ 6.8 B | USA |
 |
Medpace Holdings
MEDP
|
$ 589.29 | 0.31 % | $ 17 B | USA |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 330.56 | 0.11 % | $ 27.4 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
$ 3.19 | 1.57 % | $ 295 M | USA |
 |
ENDRA Life Sciences
NDRA
|
$ 6.0 | 0.83 % | $ 4.72 M | USA |
 |
NeoGenomics
NEO
|
$ 17.57 | 1.09 % | $ 2.25 B | USA |
 |
Neogen Corporation
NEOG
|
$ 11.92 | 0.72 % | $ 2.59 B | USA |
 |
National Research Corporation
NRC
|
$ 20.81 | 1.32 % | $ 466 M | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Natera
NTRA
|
$ 327.95 | 0.16 % | $ 44.8 B | USA |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | Schweiz |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 2.97 | 0.66 % | $ 96.4 K | USA |
|
Biodesix
BDSX
|
$ 27.42 | 4.72 % | $ 207 M | USA |
 |
Biomerica
BMRA
|
$ 2.32 | 0.39 % | $ 6.76 M | USA |
 |
Quidel Corporation
QDEL
|
$ 13.25 | 0.29 % | $ 558 M | USA |
 |
Precipio
PRPO
|
$ 26.53 | 4.9 % | $ 42.6 M | USA |
 |
Personalis
PSNL
|
$ 16.86 | 2.2 % | $ 1.5 B | USA |
 |
RadNet
RDNT
|
$ 73.02 | 0.24 % | $ 5.49 B | USA |
 |
Senseonics Holdings
SENS
|
$ 9.36 | 5.97 % | $ 391 M | USA |
 |
Neuronetics
STIM
|
$ 2.87 | 5.88 % | $ 189 M | USA |
 |
Thermo Fisher Scientific
TMO
|
$ 602.9 | 0.02 % | $ 227 B | USA |
 |
Trinity Biotech plc
TRIB
|
$ 9.04 | 0.64 % | $ 3.25 B |  Irlanda |
 |
Twist Bioscience Corporation
TWST
|
$ 126.69 | 1.58 % | $ 7.58 B | USA |
 |
Sotera Health Company
SHC
|
$ 18.73 | 0.05 % | $ 5.32 B | USA |
 |
VolitionRx Limited
VNRX
|
$ 0.34 | 2.52 % | $ 42.8 M |  Singapore |
 |
Waters Corporation
WAT
|
$ 402.5 | 0.33 % | $ 24 B | USA |
 |
Exagen
XGN
|
$ 7.44 | 0.53 % | $ 160 M | USA |
 |
DarioHealth Corp.
DRIO
|
$ 7.01 | 3.72 % | $ 27.9 M |  Israel |
 |
Agilent Technologies
A
|
$ 146.81 | 0.59 % | $ 41.7 B | USA |
 |
BioNano Genomics
BNGO
|
$ 1.2 | 0.39 % | $ 6.53 M | USA |
 |
Co-Diagnostics
CODX
|
$ 1.13 | 2.55 % | $ 1.5 M | USA |
 |
Castle Biosciences
CSTL
|
$ 32.77 | 1.03 % | $ 950 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
$ 235.53 | 2.07 % | $ 26.1 B | USA |
 |
Danaher Corporation
DHR
|
$ 205.39 | 0.53 % | $ 146 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M |  Britain |
 |
CareDx, Inc
CDNA
|
$ 49.76 | 2.05 % | $ 2.65 B | USA |
 |
ICON Public Limited Company
ICLR
|
$ 160.6 | 0.78 % | $ 12.6 B | Irlanda |